½ÃÀ庸°í¼­
»óǰÄÚµå
1587216

¼¼°èÀÇ ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå : °Ë»ç À¯Çü, ±â¼ú, ¿ëµµº° ¿¹Ãø(2025-2030³â)

Coagulation & Hemostasis Testing Market by Test Type (Activated Partial Thromboplastin Time, D-Dimer Testing, Fibrinogen Testing), Technology (Electrochemical Technology, Mechanical Technology, Optical Technology), End-Use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀåÀº 2023³â 52¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 58¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.28%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 111¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÀ°í ¹× ÁöÇ÷ °Ë»çÀÇ ¹üÀ§¿Í Á¤ÀÇ¿¡´Â Ç÷¾×À» ÀÀ°í½Ã۰í ÁöÇ÷ ±ÕÇüÀ» À¯ÁöÇÏ´Â ´É·ÂÀ» Æò°¡ÇÏ´Â Áø´Ü ÀýÂ÷¿Í ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ., ¼ö¼ú±â ¹× ÁßÁõ ȯÀÚ °ü¸® ¸Å¿ì Áß¿äÇÕ´Ï´Ù.ÀÌ Çʿ伺Àº Ç÷¿ìº´, ½ÉºÎÁ¤¸Æ Ç÷ÀüÁõ, Æó »öÀüÁõÀÇ Áø´Ü, ½ÉÀ庴 °ü¸® ¸ð´ÏÅ͸µ µîÀÇ ÀÓ»ó ÀÀ¿ë¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ¼¾ÅÍ µîÀÔ´Ï´Ù. ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç ±â¼úÀÇ Áøº¸, ½ÅÈï±¹ÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó °­È­ µîÀÌ ÀÖ½À´Ï´Ù. ÀáÀç ±âȸ´Â Áø´Ü Á¤È®µµ¿Í È¿°ú ¼Óµµ¸¦ ³ôÀ̱â À§ÇÑ ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕ, ¸ÂÃãÇü ÀÇ·á, ÀçÅà ÇコÄɾî ȯ°æ¿¡ ´ëÀÀÇÏ´Â ÈÞ´ë¿ë °Ë»ç ±â±âÀÇ °³¹ß¿¡ ÀÖ½À´Ï´Ù. °³¹ß Áö¿ªÀÇ ÇѰè ÀÌ·¯ÇÑ Àνİú °°Àº °úÁ¦°¡ Å« Àå¾Ö°¡ µÇ°í ÀÖ½À´Ï´Ù., º¸´Ù Á¤È® ÀÀ°í ÇÁ·ÎÆÄÀÏÀ» ¾ò±â À§ÇÑ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Å½»ö, ±â¼ú Çõ½Å¿¡ ÀÇÇÑ ºñ¿ëÈ¿°úÀÇ °³¼±, ¿ø°ÝÀÇ·á±â´ÉÀÇ È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÆûÀÇ È®´ë °æÇâÀ» ÀÌ¿ëÇÔÀ¸·Î½á ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. È«º¸Çϱâ À§ÇØ ±â¾÷ Àü·«Àû Àμö¿Í Á¦ÈÞ¿¡ ´ëÇÑ ÅõÀÚ, Á¦Ç° Æ÷Æ®Æú¸®¿À °­È­, ¹Ì°³Ã´ ½ÃÀåÀ¸·ÎÀÇ Áö¸®Àû µµ´Þ¹üÀ§ È®´ë¸¦ °í·ÁÇØ¾ß ÇÕ´Ï´Ù. ±ÕÇüÀ» À¯ÁöÇÏ´Â °ÍÀÌ ¿©ÀüÈ÷ Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 52¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 58¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 111¾ï 8,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 11.28%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ÀÀ°í ¹× ÁöÇ÷°Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³

ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°èÀÇ ½ÉÇ÷°ü Áúȯ ¹× Ç÷¾× ÁúȯÀÇ À¯º´·üÀÇ »ó½Â
    • Áø´Ü ½ÇÇè½Ç¿¡¼­ ÀÚµ¿ ÁöÇ÷ ÀåÄ¡ÀÇ Ã¤¿ë Áõ°¡
    • Ç÷¿ìº´ÀÇ °è¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀÇ ÀÌ¿ë °¡´É¼º
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀüÀÚµ¿ ÀÀ°í ½Ã½ºÅÛ°ú °ü·ÃµÈ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) ÀÀ°í °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ÀÀ°í ¹× ÁöÇ÷ °Ë»ç¿¡ À־ÀÇ ±â¼úÀÇ Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ö°ÝÈ÷ ½Ã°£ÀÌ °É¸®´Â ±ÔÁ¦ ÇÁ·Î¼¼½º

Porter's Five Forces : ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ã´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå¿¡¼­°æÀï ±¸µµÀÇ ÆÄ¾Ç

ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ½ÇÀûÀ» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´×, ¸ÅÆ®¸¯½º ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼®°ú Ãßõ ÀÀ°í ¹× ÁöÇ÷°Ë»ç ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÀÖ¾î ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» ÀÌ·ç±â À§ÇÑ ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°èÀûÀ¸·Î ½ÉÇ÷°üÁúȯ°ú Ç÷¾×ÁúȯÀÇ ÀÌȯÀ²ÀÌ »ó½Â
      • Áø´Ü ½ÇÇè½Ç¿¡ À־ÀÇ ÀÚµ¿ ÁöÇ÷ ÀåÄ¡ÀÇ µµÀÔ Áõ°¡
      • Ç÷¿ìº´ÀÇ °è¹ß¿¡ ÁßÁ¡À» µÐ Á¤ºÎÀÇ ´ëóÀÇ À¯¹«
    • ¾ïÁ¦¿äÀÎ
      • ¿ÏÀü ÀÚµ¿È­ ÀÀ°í ½Ã½ºÅÛ¿¡ µû¸¥ °íºñ¿ë
    • ±âȸ
      • Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) ÀÀ°í °Ë»ç ¼ö¿ä Áõ°¡
      • ÀÀ°í ¹× ÁöÇ÷ °Ë»ç¿¡ À־ÀÇ ±â¼úÀû Áøº¸
    • °úÁ¦
      • ¾ö°ÝÇÏ°í ½Ã°£ÀÌ °É¸®´Â ±ÔÁ¦ ÇÁ·Î¼¼½º
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå Å×½ºÆ® À¯Çüº°

  • Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • D ´ÙÀÌ¸Ó °Ë»ç
  • ÇǺ긮³ë°Õ °Ë»ç
  • Ç÷¼ÒÆÇ ±â´É °Ë»ç

Á¦7Àå ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå : ±â¼úº°

  • Àü±âÈ­ÇÐ ±â¼ú
  • ±â°è±â¼ú
  • ±¤ÇÐ ±â¼ú

Á¦8Àå ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • Áø´Ü¼¾ÅÍ
  • º´¿ø
  • Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÀ°í ¹× ÁöÇ÷ °Ë»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Danaher Corporation
  • Diagnostica Stago SAS
  • F. Hoffmann-La Roche Ltd.
  • George King Bio-Medical, Inc.
  • Grifols, SA
  • Helena Laboratories Corporation
  • Medtronic PLC
  • Micropoint Biotechnologies Co., Ltd
  • Sekisui Chemical Co., Ltd.
  • Siemens AG
  • Sysmex Corporation
  • Tcoag Ireland Limited
  • Thermo Fisher Scientific Inc.
  • Werfen, SA
BJH 24.11.15

The Coagulation & Hemostasis Testing Market was valued at USD 5.29 billion in 2023, expected to reach USD 5.88 billion in 2024, and is projected to grow at a CAGR of 11.28%, to USD 11.18 billion by 2030.

The scope and definition of coagulation and hemostasis testing encompass diagnostic procedures and technologies used to evaluate the blood's ability to clot and maintain hemostatic balance. This testing is crucial in identifying bleeding disorders, guiding anticoagulant therapy, and managing perioperative and critical care patients. Its necessity spans across clinical applications such as diagnosing hemophilia, deep vein thrombosis, pulmonary embolism, and monitoring heart disease management. End-users primarily include hospitals, diagnostic laboratories, and outpatient surgical centers. Key growth factors influencing this market include the increasing prevalence of cardiovascular diseases, rising elderly population, advancements in technology with point-of-care testing, and enhanced healthcare infrastructure in emerging economies. The latest potential opportunities lie in the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and efficiency, personalized medicine, and the development of portable testing devices that cater to home healthcare settings. However, challenges such as high cost of advanced testing equipment, stringent regulatory approvals, and limited awareness in developing regions pose significant hurdles. A focus on continuous innovation, regulatory compliance, and strategic partnerships can mitigate these limitations. Promising areas of research and innovation include the exploration of novel biomarkers for more precise coagulation profiles, improving cost-effectiveness through technological innovations, and expanding telemedicine capabilities. Businesses can gain insights into market dynamics by tapping into the growing trend of remote diagnostics and telehealth platforms, which were accelerated by the COVID-19 pandemic. The nature of the market is highly competitive with a mix of established players and startups driving substantial research and development. To foster business growth, companies should consider investing in strategic acquisitions or collaborations, enhancing product portfolios, and expanding geographical reach to underserved markets. Balancing technological innovation with affordability and accessibility remains crucial for sustained market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 5.29 billion
Estimated Year [2024] USD 5.88 billion
Forecast Year [2030] USD 11.18 billion
CAGR (%) 11.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Coagulation & Hemostasis Testing Market

The Coagulation & Hemostasis Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the Prevalence of cardiovascular diseases and blood disorders globally
    • Increasing adoption of automated hemostasis equipment in diagnostic laboratories
    • Availability of government initiatives focusing on awareness of hemophilia
  • Market Restraints
    • High cost associated with fully automated coagulation systems
  • Market Opportunities
    • Rising demand for point of care (POC) coagulation testing
    • Technological advancements in coagulation & hemostasis testing
  • Market Challenges
    • Stringent and time-consuming regulatory processes

Porter's Five Forces: A Strategic Tool for Navigating the Coagulation & Hemostasis Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Coagulation & Hemostasis Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Coagulation & Hemostasis Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Coagulation & Hemostasis Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Coagulation & Hemostasis Testing Market

A detailed market share analysis in the Coagulation & Hemostasis Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Coagulation & Hemostasis Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Coagulation & Hemostasis Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Coagulation & Hemostasis Testing Market

A strategic analysis of the Coagulation & Hemostasis Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Coagulation & Hemostasis Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Danaher Corporation, Diagnostica Stago SAS, F. Hoffmann-La Roche Ltd., George King Bio-Medical, Inc., Grifols, S.A., Helena Laboratories Corporation, Medtronic PLC, Micropoint Biotechnologies Co., Ltd, Sekisui Chemical Co., Ltd., Siemens AG, Sysmex Corporation, Tcoag Ireland Limited, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Coagulation & Hemostasis Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Activated Partial Thromboplastin Time, D-Dimer Testing, Fibrinogen Testing, and Platelet Function Tests.
  • Based on Technology, market is studied across Electrochemical Technology, Mechanical Technology, and Optical Technology.
  • Based on End-Use, market is studied across Diagnostic Centers, Hospitals, and Point-of-Care Testing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the Prevalence of cardiovascular diseases and blood disorders globally
      • 5.1.1.2. Increasing adoption of automated hemostasis equipment in diagnostic laboratories
      • 5.1.1.3. Availability of government initiatives focusing on awareness of hemophilia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with fully automated coagulation systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising demand for point of care (POC) coagulation testing
      • 5.1.3.2. Technological advancements in coagulation & hemostasis testing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and time-consuming regulatory processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Coagulation & Hemostasis Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Activated Partial Thromboplastin Time
  • 6.3. D-Dimer Testing
  • 6.4. Fibrinogen Testing
  • 6.5. Platelet Function Tests

7. Coagulation & Hemostasis Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Electrochemical Technology
  • 7.3. Mechanical Technology
  • 7.4. Optical Technology

8. Coagulation & Hemostasis Testing Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals
  • 8.4. Point-of-Care Testing

9. Americas Coagulation & Hemostasis Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Coagulation & Hemostasis Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Coagulation & Hemostasis Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Danaher Corporation
  • 3. Diagnostica Stago SAS
  • 4. F. Hoffmann-La Roche Ltd.
  • 5. George King Bio-Medical, Inc.
  • 6. Grifols, S.A.
  • 7. Helena Laboratories Corporation
  • 8. Medtronic PLC
  • 9. Micropoint Biotechnologies Co., Ltd
  • 10. Sekisui Chemical Co., Ltd.
  • 11. Siemens AG
  • 12. Sysmex Corporation
  • 13. Tcoag Ireland Limited
  • 14. Thermo Fisher Scientific Inc.
  • 15. Werfen, S.A.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦